A common functional consequence of tumor-derived mutations within c-MYC

Oncogene

Volumn 34, Issue 18, 2015, Pages 2406-2409

  Chakraborty, A A ^a,b,d   Scuoppo, C ^a,e   Dey, S ^b,f   Thomas, L R ^b   Lorey, S L ^b   Lowe, S W ^a,c,g   Tansey, W P ^a,b  

^a Simons Center for Quantitative Biology   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Columbia University ^*  (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MYC PROTEIN; MYC PROTEIN, HUMAN;

3T3 CELL LINE; AMINO ACID SEQUENCE; ANIMAL; GENETICS; HUMAN; LYMPHOMA; METABOLISM; MISSENSE MUTATION; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CONSERVED SEQUENCE; DNA; HUMANS; LYMPHOMA; MICE; MUTATION, MISSENSE; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84940297439     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.186     Document Type: Article

References (23)

1. Rabbitts TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 1983; 306: 760-765.
2. Westaway D, Payne G, Varmus HE. Proviral deletions and oncogene basesubstitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors. Proc Natl Acad Sci USA 1984; 81: 843-847.
3. Showe LC, Ballantine M, Nishikura K, Erikson J, Kaji H, Croce CM. Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line alpha switch region. Mol Cell Biol 1985; 5: 501-509.
4. Murphy W, Sarid J, Taub R, Vasicek T, Battey J, Lenoir G et al. A translocated human c-myc oncogene is altered in a conserved coding sequence. Proc Natl Acad Sci USA 1986; 83: 2939-2943.
5. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56-61.
6. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 1994; 84: 883-888.
7. Clark HM, Yano T, Otsuki T, Jaffe ES, Shibata D, Raffeld M. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res 1994; 54: 3383-3386.
8. Axelson H, Henriksson M, Wang Y, Magnusson KP, Klein G. The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas. Eur J Cancer 1995; 31A: 2099-2104.
9. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811.
10. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
11. Giulino-Roth L, Wang K, MacDonald TY, Mathew S, Tam Y, Cronin MT et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012; 120: 5181-5184.
12. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-1325.
13. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc. Embo J 1999; 18: 717-726.
14. Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004; 101: 9085-9090.
15. Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M et al. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: Transrepression correlates with acceleration of apoptosis. Mol Cell Biol 2000; 20: 6008-6018.
16. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011; 71: 925-936.
17. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
18. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558-6562.
19. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
20. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1: 352-365.
21. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
22. Tworkowski KA, Chakraborty AA, Samuelson AV, Seger YR, Narita M, Hannon GJ et al. Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. Proc Natl Acad Sci USA 2008; 105: 6103-6108.
23. Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep 2005; 6: 177-183.